News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website

Boston Life Sciences Announces Successful Results in its New Class of Parkinson`s Disease --PD-- Therapy Tested in Primates (Business Wire)...Blocking the DAT allows for a transient build-up of the brain`s own dopamine (a neurotransmitter surrounding nerve terminals),......a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders;...- May 10 8:03 AM ET

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)


Posted on: 05/10/2001

"Yahoo - Boston Life Sciences Announces Successful Results in its New Class of Parkinson's Disease --PD-- Therapy Tested in Primates"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]

Related Quotes
delayed 20 mins - disclaimer

Thursday May 10, 8:03 am Eastern Time

Press Release

Boston Life Sciences Announces Successful Results in its New Class of Parkinson's Disease --PD-- Therapy Tested in Primates

Dopamine Transporter-blocking drug reverses behavioral and motor defects in primates with PD without causing significant side effects

BOSTON--(BW HealthWire)--May 10, 2001-- Boston Life Sciences, Inc. (NASDAQ:BLSI - news) today announced that the Company's experimental drug O-1369 improved specific motor functioning in primates with chemically induced Parkinson's Disease (PD). These results were obtained without causing the significant side effects often associated with existing PD treatments. O-1369 represents a new class of potential therapeutic compounds for PD that maximize the beneficial effect of the patient's own available dopamine production. The drug is designed to selectively block the dopamine transporter (DAT) and thus inhibit the reuptake of such dopamine. Blocking the DAT allows for a transient build-up of the brain's own dopamine (a neurotransmitter surrounding nerve terminals), thus generating localized levels high enough to offset the overall deficiency in dopamine production and release caused by PD.

In this study, monkeys with chemically induced mild to moderate PD were given increasing doses of the DAT blocking drug O-1369 and were then videotaped for six hours. PD-specific motor behaviors were then rated in a blinded fashion from the videotape. Significant improvement was seen in posture, rigidity, tremors, bradykinesia and body freeze. The improvement was related to dose levels, and was consistent with that seen in conventional therapies for PD such as dopamine D1 receptor agonists.

"We believe that this new class of PD therapeutics, if clinically successful, may offer relatively few side effects compared to current therapies. Of additional great importance is that O-1369 will not only add to the options available for the treatment of PD, but may also favorably alter the underlying pathology of the disease, since the DAT has been implicated as one of the important mediators of disease progression in PD. This is the second primate study demonstrating the potential therapeutic effectiveness of O-1369 in PD," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. "We are working to bring this exciting new therapeutic into clinical testing as quickly as possible," added Dr. Lanser.

O-1369 is the latest in a series of development products to come out of the Company's DAT platform technology. The Company's collaborating scientists were the first to design a clinically useful radioimaging agent that targeted the DAT for diagnosing early PD, as well as Attention Deficit/Hyperactivity Disorder (ADHD). This product, Altropane, has been used successfully in both a Phase III study in PD and a Phase II study in ADHD and is pending submission to the FDA for marketing approval. A second-generation technetium-based DAT radioimaging agent is presently in advanced pre-clinical studies. Subsequent DAT research resulted in the synthesis of a number of DAT blockers with potential therapeutic applications, of which O-1369 is the lead candidate. In addition to its therapeutic use in PD, the Company is initiating a preclinical development program using O-1369 to treat ADHD. People with ADHD show abnormally high levels of Dopamine Transporters, while those with PD show markedly decreased levels.

"We are thrilled with the results of this study. It further validates the role that Dopamine Transporters play in neurological disorders such as Parkinson's Disease and Attention Deficit/Hyperactivity Disorder," said David Hillson, CEO of Boston Life Sciences. "It also demonstrates the leadership role that Boston Life Sciences is establishing in the treatment and diagnosis of CNS disorders. We have developed a new class of pharmacology that targets the Dopamine Transporters. With about 500,000 Americans and 4 million individuals worldwide currently diagnosed with PD, this represents a potentially substantial therapeutic market for O-1369. Our DAT program has produced a much-needed objective diagnostic for Attention Deficit/Hyperactivity Disorder (ADHD), a new class of PD therapy, an exciting potential ADHD therapy, a diagnostic and therapeutic approach to age-related depression and other second-generation diagnostics."

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: Altropane and Fluoratec, radioimaging agents for the diagnosis of PD and ADHD; Troponin, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact may represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.

     Investors                     Media
     Boston Life Sciences, Inc.    Noonan/Russo Communications
     Maria Zapf                    Lynn Blenkhorn
     617.425.0200, ext.17          212.696.4455, ext. 241
     Boston Life Sciences, Inc.
     Marc Lanser
     617.425.0200, ext. 13

Email this story - Most-emailed articles - Most-viewed articles

More Quotes and News:Boston Life Sciences Inc (NasdaqNM:BLSI - news)
Related News Categories: biotech, health care, medical/pharmaceutical


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557